BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

Lauren Silvis has joined personalized medicine company Tempus Labs Inc. (Chicago, Ill.) as SVP of external affairs. Silvis was FDA chief of staff from May 2017 to June 2019; she also served for two years...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...
BioCentury | Feb 1, 2016
Finance

Emerging in Denmark

After three years of testing the waters, the board of Lundbeck Foundation wants to ramp up its early stage investing. The group has tasked its Lundbeckfond Emerge unit with investing about €40 million ($40.4 million)...
BioCentury | Jan 11, 2016
Financial News

IO Biotech completes venture financing

IO Biotech ApS , Copenhagen, Denmark Business: Cancer Date completed: 2016-01-05 Type: Venture financing Raised: EUR11 million ($12 million) Investors: Lundbeckfond Emerge; Novo A/S WIR Staff cancer...
BioCentury | Jan 6, 2016
Financial News

IO Biotech raises EUR 11M in series A

Immuno-oncology play IO Biotech ApS (Copenhagen, Denmark) raised EUR 11 million ($12 million) in a series A round from new investor Lundbeckfond Emerge and existing investor Novo A/S (Hellerup, Denmark). Lundbeckfond Emerge is the early...
BioCentury | Jan 19, 2015
Financial News

IO Biotech completes venture financing

IO Biotech ApS , Copenhagen, Denmark Business: Cancer Date completed: 2015-01-12 Type: Venture financing Raised: EUR3 million ($3.5 million) Investor: Novo Seeds WIR Staff cancer...
Items per page:
1 - 7 of 7
BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

Lauren Silvis has joined personalized medicine company Tempus Labs Inc. (Chicago, Ill.) as SVP of external affairs. Silvis was FDA chief of staff from May 2017 to June 2019; she also served for two years...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...
BioCentury | Feb 1, 2016
Finance

Emerging in Denmark

After three years of testing the waters, the board of Lundbeck Foundation wants to ramp up its early stage investing. The group has tasked its Lundbeckfond Emerge unit with investing about €40 million ($40.4 million)...
BioCentury | Jan 11, 2016
Financial News

IO Biotech completes venture financing

IO Biotech ApS , Copenhagen, Denmark Business: Cancer Date completed: 2016-01-05 Type: Venture financing Raised: EUR11 million ($12 million) Investors: Lundbeckfond Emerge; Novo A/S WIR Staff cancer...
BioCentury | Jan 6, 2016
Financial News

IO Biotech raises EUR 11M in series A

Immuno-oncology play IO Biotech ApS (Copenhagen, Denmark) raised EUR 11 million ($12 million) in a series A round from new investor Lundbeckfond Emerge and existing investor Novo A/S (Hellerup, Denmark). Lundbeckfond Emerge is the early...
BioCentury | Jan 19, 2015
Financial News

IO Biotech completes venture financing

IO Biotech ApS , Copenhagen, Denmark Business: Cancer Date completed: 2015-01-12 Type: Venture financing Raised: EUR3 million ($3.5 million) Investor: Novo Seeds WIR Staff cancer...
Items per page:
1 - 7 of 7